Yes, Guts, iHack is a disappointment. I have stop

Yes, Guts, iHack is a disappointment. I have stopped reading that board and will stick to the Hangout with an occasional post on the YMB, including this one in response to the million dollar question about the mysterious percentage of revenues to which Scrips is entitled from the speciality pharm marketing agreement:

D - I wish I knew, but I will speculate that the use of the term "significant percentage of its revenues" implies much more than the 20% of gross profits from WRx but less than the 90% from PIMD revenues. My bet is on 50% or more of the revenues. At least that's what I would consider "significant". Assuming 51%, Scrips would report $327,556 from the specialty pharm revs in Q1. I suspect we will learn the details from the Q1 report in May. But let's assume I'm correct, and further assume $126K from SCRC's 20% share of the WRx gross profits (assume $900K in Q1 revs from WRx), and $19K from the contract packager revs. (We still have no information about the PIMD business or whether the company shipped the $200K RapiMeds order to Hong Kong.) So, Scrips would report first quarter revenues of about $473K. And considering the company's total 2013 revs were only $559K per the late 10K filing notice today, reporting a first quarter number that's about 85% of the total revs for last year will not go unnoticed by the market. The stock price will catch up. And those savvy enough to connect the dots and invest in this hidden gem will be rewarded.